Alnylam Pharmaceuticals
ALNY
238 hedge funds and large institutions have $6.73B invested in Alnylam Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 106 increasing their positions, 59 reducing their positions, and 22 closing their positions.
114% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 22
80% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 59
33% more call options, than puts
Call options by funds: $84.9M | Put options by funds: $63.7M
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
20% more capital invested
Capital invested by funds: $5.63B → $6.73B (+$1.1B)
10% more funds holding
Funds holding: 216 → 238 (+22)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$151M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$119M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$104M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$80.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$103M |
| 2 |
AWG
Alpha Wave Global
New York
|
-$50.3M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$20.5M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$20.2M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$16.5M |
ALNY Hedge Fund Activity: Q1 2015 in Review
238 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2015, worth a combined $6.73B — up 20% from $5.63B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new ALNY positions and 22 closed out — a net gain of 25 holders — while 106 added to existing stakes and 59 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $151M. The largest seller was Franklin Resources, cutting an estimated $103M.
- 238 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2015, up from 216 in Q4 2014.
- Funds reported $6.73B of Alnylam Pharmaceuticals stock for Q1 2015, up 20% quarter-over-quarter.
- 47 funds opened new Alnylam Pharmaceuticals positions in Q1 2015 and 22 closed out, a net change of +25 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2015 was Wellington Management Group, an estimated $151M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2015 was Franklin Resources, an estimated $103M sold.
Based on aggregated 13F filings for Q1 2015.